BASECARE-B

2170
1.3352.55% ( -0.035 )
Delay Closed: Nov 16, 16:08:00

Overview

BASECARE-B (2170)

Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People’s Re...

Open
1.400
High
1.400
Low
1.295
Prev. Close
1.370
Volume
64.00K
Turnover
86.76K
Avg Price
1.356
Bid/Ask Ratio
-25.58%
Amplitude
7.66%
52wk High
2.470
Volume Ratio
2.98
Turnover Ratio
0.08%
52wk Low
1.200
HK Mkt Cap
109.66M
Market CapHKD
364.39M
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.734
EPSDynamic
-0.608
EPSStatic
--
BVPS
3.65
P/B
0.37
HK Shares
82.14M
Dividend YieldTTM
--
DividendTTM
--
Shares
272.95M
Min lot size
500
Currency
HKD

BASECARE-B Analyst Rating

View more

Forecast & Rating

Jul 1, 2026
Price forecast
HK$1.6019.92%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    BaseCare Medical (2170.HK) spiked and faded, opening at HK$1.400, which was also the session high, before sliding to HK$1.300 at 11:20 BJ and closing at HK$1.335, down 2.55% on just 64,000 shares. Repeated next-day disclosure returns tied to its RMB5 million buy-back and a cumulative repurchase programme still failed to hold the HK$1.40 level. H1 FY2026 revenue rose 27% to RMB128.75 million with the net loss narrowing 40.7% to RMB72.05 million, while Q2 revenue of HK$74.36 million grew 33.9% year on year yet net margin stayed at -55.96%. At HK$1.335 the stock sits on MA60 of HK$1.333 and below MA20 of HK$1.346, down 32.23% year to date and 45.95% below the 52-week high of HK$2.47. Though the absolute loss and ROE of -16.66% indicate the earnings inflection is not yet confirmed.

  2. Nov, 4

    BaseCare Medical probed lower and recovered, closing at HK$1.35, down 0.7% from the prior close of HK$1.36: it opened at the session high of HK$1.36, slid to HK$1.27 by 10:53 BJ, then clawed back to HK$1.35 by the 16:00 close on just 80,500 shares and HK$108,855 of turnover (0.10% turnover rate), suggesting selling pressure eased after the prior session's roughly 7% drop. Support traces to buybacks, including 43,000 shares for HK$58,700 on November 2 and a near-daily repurchase run through late October, alongside State Council language on a birth-friendly society that lifted maternal and infant themes. Fundamentals remain in loss-narrowing mode: Q2 2026 revenue of HK$74.36 million rose 33.9% year on year, net loss narrowed 37.5% to HK$41.61 million and operating loss improved 48.55%, yet net margin stayed at -55.96%, with PB 0.37 and market cap HK$368.7 million. The stock is down 31.47% year to date, 50.4% below its 52-week high of HK$2.72 and 12.5% above the HK$1.20 low, now above MA20 of 1.324 and MA60 of 1.341, though it remains unprofitable and buyback size is small relative to market cap.

  3. Oct, 23

    Basecare Medical (2170.HK) closed down 2.55% at HK$1.335 on 23 October, shaping a low-open, dip-then-rebound session with a late fade, ranging between HK$1.285 and HK$1.365 on just 85,000 shares and a 0.1% turnover rate. Support came mainly from continuous buybacks: 31,500 shares for HK$43,500 on 22 October, plus 25,500 and 19,500 shares on the 21st and 20th, alongside an H-share repurchase plan capped at RMB 5 million; in September the GEMS vitrification and thawing solution set won a Class III device registration certificate. Q2 2026 revenue reached HK$74.36 million, up 33.92% year on year, with net loss narrowing 37.48% to HK$41.61 million, though the net margin stayed at -55.96%. The stock sits 54.9% below its 52-week high of HK$2.96 and down 32.23% year to date, holding above the 1.291 MA20 but below the 1.349 MA60, with a 0.37 price-to-book. Still, the single-day repurchase size is small, so the bid around HK$1.3 remains to be tested.

  4. Oct, 22

    Successive buybacks and a narrower interim loss lifted 2170.HK 1.48% to HK$1.37, after an afternoon slide to HK$1.29 that was recovered into the close. Basecare repurchased 25,500 shares for HK$34,500 on 21 October, extending a run of small buybacks since 9 October alongside a planned H-share repurchase of up to RMB5 million. Q2 2026 revenue reached HK$74.36 million, up 33.92% year on year, while net loss narrowed to HK$41.61 million, a 37.48% reduction, though net margin stayed at -55.96%. Still, the stock is down 30.46% year to date and sits 53.72% below its 52-week high of HK$2.96, trading above the MA20 of 1.294 with price-to-book at 0.38 times and only HK$45,470 of turnover for the session.

  5. Sep, 24

    Suzhou Basecare Medical opened lower and drifted downward during the morning session, falling from an opening of 1.395 HKD to 1.300 HKD, a decline of 6.81%, with 321 thousand shares traded and turnover of 417,905 HKD. The primary driver was the company's first half FY2026 financial results: net loss narrowed by 40.7% year-over-year to RMB 72.05 million, but revenue grew only 27% to RMB 128.75 million, and the quarterly net profit margin remained at -55.96% with EPS of -0.152 HKD. Positive catalysts such as the NMPA Class III approval for the Gems embryo culture medium and a strategic partnership with RHEA LABS were overshadowed by the persistent losses. The stock now trades at 1.30 HKD, 60.49% below its 52-week high of 3.29 HKD, down 34.01% year-to-date, and below both its 20-day MA of 1.357 HKD and 60-day MA of 1.38 HKD.

News